Stay updated on Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.

Latest updates to the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page
- ChecktodayChange DetectedThe page now shows Revision: v3.6.5, replacing the prior v3.6.4 as part of a maintenance build. This update changes the release identifier without altering study content or user-facing features.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a new version of the page. This reflects a behind-the-scenes update rather than a change to the study information itself.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page has been updated to a new version (v3.6.3), indicating a routine maintenance update to the study details page.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, representing a new publication version of the page. No visible changes to study details or other information are indicated.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page now displays recruitment status as 'No longer looking for participants', indicating the study is not enrolling. It also adds helper sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and updates the footer to 'Revision: v3.6.0' while adjusting the 'Intervention/Treatment' heading and removing 'Revision: v3.5.5'.SummaryDifference0.4%

- Check65 days agoChange DetectedThe page has been updated to version v3.5.5 from v3.5.4, representing a small internal update to the page rather than changes to study details.SummaryDifference0.1%

Stay in the know with updates to Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.